Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Roivant Sciences (ROIV) Stock Price & Analysis
382 Followers
ROIV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.06 - $13.24
Previous Close$10.36
Volume3.42M
Average Volume (3M)7.43M
Market Cap
$8.35B
Enterprise Value$2.68B
Total Cash (Recent Filing)$6.67B
Total Debt (Recent Filing)$506.58M
Price to Earnings (P/E)2.0
Beta0.89
Next Earnings
Jun 26, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.21
Shares Outstanding805,846,006
10 Day Avg. Volume5,477,530
30 Day Avg. Volume7,427,250
Standard Deviation0.22
R-Squared0.16
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.45
Price to Sales (P/S)252.88
Price to Cash Flow (P/CF)-10.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.47
Enterprise Value/Gross Profit43.72
Enterprise Value/Ebitda0.60
Forecast
1Y Price Target
$17.00Price Target Upside64.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Roivant Sciences News
Bulls Say, Bears Say
Bulls Say
Drug Development And Market PotentialBrepocitinib shows 'best-in-class' potential in non-infectious uveitis, meeting all primary and secondary endpoints, signaling a strong market presence if approved.
Financial StrategyROIV's share repurchase program, valued at $1.5 billion, aims to optimize shareholder value and reflects the company's strong cash position.
Legal And Patent SuccessROIV's legal victories in patent disputes and potential favorable settlement could significantly enhance their financial outlook.
Bears Say
Legal ChallengesMRNA faced a setback as the judge favored ROIV's broader interpretations of disputed patent claims, implying difficulties for MRNA in the litigation.
Product RevenueVtama sales ended below consensus and estimates, indicating a slower growth than expected.
Sales PerformanceSales of VTAMA were slightly below consensus, affected by a lower than expected gross-to-net yield.
---
Ownership Overview
65.15% Insiders
7.50% Mutual Funds
6.38% Other Institutional Investors
20.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.06 and its highest was $13.24 in the past 12 months.
What is Roivant Sciences’s market cap?
Currently, no data Available
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Jun 26, 2024 which is in 68 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Feb 13, 2024. The company reported $6.03 earnings per share for the quarter, beating the consensus estimate of -$0.309 by $6.339.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -$0.28.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 805,846,000 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of $6.03 in its last earnings report, beating expectations of -$0.309. Following the earnings report the stock price went down -0.644%.
Which hedge fund is a major shareholder of Roivant Sciences?
Among the largest hedge funds holding Roivant Sciences’s share is Viking Global Investors LP. It holds Roivant Sciences’s shares valued at 779M.
---
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (64.09% Upside)
$17.00 (64.09% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $373.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.53%
12-Months-Change
Fundamentals
Return on Equity
123.54%
Trailing 12-Months
Asset Growth
231.95%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q3 2024
0:00 / 0:00
---
ROIV Stock 12 Months Forecast
Average Price Target
$17.00
▲(64.09% Upside)
Technical Analysis
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+74.75%
assigned a buy rating 8 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +74.75% per trade.
---